Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph P Balthasar

Showing results (41-50 of 88) with videos related to

Pageof 9
Sort By:
Antibodies (Basel, Switzerland)|September 24, 2019
Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial InfectionsShun Xin Wang-Lin, Joseph P Balthasar
Cancers|March 28, 2025
Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic IndexJue Gong, Wenqiu Zhang, Joseph P Balthasar
The AAPS Journal|August 30, 2017
Investigation of the Influence of Protein-Losing Enteropathy on Monoclonal Antibody Pharmacokinetics in MiceYujie Yang, Tommy R Li, Joseph P Balthasar
Journal of Clinical Pharmacology|February 25, 2015
Assessments of antibody biodistributionPatrick M Glassman, Lubna Abuqayyas, Joseph P Balthasar
Cancer Research|March 17, 2021
Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 EfficacyBrandon M Bordeau, Yujie Yang, Joseph P Balthasar
Journal of Pharmacokinetics and Pharmacodynamics|September 14, 2015
Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeysPatrick M Glassman, Yang Chen, Joseph P Balthasar
The AAPS Journal|April 6, 2006
Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopeniaFeng Jin, Zia R Tayab, Joseph P Balthasar
The AAPS Journal|June 4, 2025
Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab FragmentsJue Gong, Brandon M Bordeau, Joseph P Balthasar
Journal of Pharmacokinetics and Pharmacodynamics|September 3, 2013
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodiesYanguang Cao, Joseph P Balthasar, William J Jusko
Pharmaceutical Research|November 9, 2013
Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathyFrank A Engler, Bo Zheng, Joseph P Balthasar
Pageof 9

Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Antibodies (Basel, Switzerland)|September 24, 2019
Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial InfectionsShun Xin Wang-Lin, Joseph P Balthasar
Cancers|March 28, 2025
Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic IndexJue Gong, Wenqiu Zhang, Joseph P Balthasar
The AAPS Journal|August 30, 2017
Investigation of the Influence of Protein-Losing Enteropathy on Monoclonal Antibody Pharmacokinetics in MiceYujie Yang, Tommy R Li, Joseph P Balthasar
Journal of Clinical Pharmacology|February 25, 2015
Assessments of antibody biodistributionPatrick M Glassman, Lubna Abuqayyas, Joseph P Balthasar
Cancer Research|March 17, 2021
Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 EfficacyBrandon M Bordeau, Yujie Yang, Joseph P Balthasar
Journal of Pharmacokinetics and Pharmacodynamics|September 14, 2015
Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeysPatrick M Glassman, Yang Chen, Joseph P Balthasar
The AAPS Journal|April 6, 2006
Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopeniaFeng Jin, Zia R Tayab, Joseph P Balthasar
The AAPS Journal|June 4, 2025
Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab FragmentsJue Gong, Brandon M Bordeau, Joseph P Balthasar
Journal of Pharmacokinetics and Pharmacodynamics|September 3, 2013
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodiesYanguang Cao, Joseph P Balthasar, William J Jusko
Pharmaceutical Research|November 9, 2013
Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathyFrank A Engler, Bo Zheng, Joseph P Balthasar
Pageof 9